Table 4.
COVID-19 therapies
| COVID-19 therapies | Total (n = 71) | DEL (n = 25) | SMI (n = 13) | NSMI (n = 33) | Group comparisons | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DEL-SMI-NSMI | DEL-SMI | DEL-NSMI | SMI-NSMI | |||||||||
| N (%) | N (%) | N (%) | N (%) | χ2 | p | χ2 | p | χ2 | p | χ2 | p | |
| Any drug | 62 (87.3) | 24 (96) | 8 (61.5) | 30 (90.9) | 9.892 | 0.007 | F’s* | 0.012 | F’s* | 0.418 | F’s* | 0.031 |
| Hydroxy chloroquine | 58 (81.7) | 24 (96) | 7 (53.8) | 27 (81.8) | 10.161 | 0.006 | F’s* | 0.004 | F’s* | 0.106 | F’s* | 0.061 |
| Azithro mycin | 53 (74.6) | 20 (80) | 8 (61.5) | 25 (75.8) | 1.58 | 0.454 | – | – | – | – | – | – |
| Lopinavir-ritonavir | 50 (70.4) | 20 (80) | 5 (38.5) | 25 (75.8) | 7.927 | 0.019 | F’s* | 0.019 | 0.147 | 0.701 | F’s* | 0.021 |
| Corticoste roids | 17 (23.9) | 8 (32) | 1 (7.7) | 8 (24.2) | 2.778 | 0.249 | – | – | – | – | – | – |
| Tocilizumab | 17 (23.9) | 7 (28) | 1 (7.7) | 9 (27.3) | 2.312 | 0.315 | – | – | – | – | – | – |
| Other | 20 (28.2) | 10 (40) | 2 (15.4) | 8 (24.2) | 3.031 | 0.220 | – | – | – | – | – | – |
* χ2: Chi-squared statistic; *p: P value; *F’s: Fisher’s test; *DEL: Patients with delirium; *SMI: Patients with severe mental illness; *NSMI: Patients with non-severe mental illness